7 completed, 2 not yet recruiting, 2 recruiting, 1 active not recruiting. 7 Phase 2, 4 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 5, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 4 | Completed 2, Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 4 | Completed 2, Active not recruiting 1, Not yet recruiting 1 |
Follow Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents Efsubaglutide Alfa 5 mg QW, Efsubaglutide Alfa 10 mg QW, Efsubaglutide Alfa 20 mg QW - Adolescence Obesity | Phase 1 | Recruiting | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | 36 | 2026-07-16 | 2026-07-30 |
| A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil Efsubaglutide Alfa Injection, Placebo - Diabete Type 2 | Phase 1 | Not yet recruiting | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | 48 | 2026-06-01 | 2026-04-08 |
| The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity（SPARKLE） Efsubaglutide Alfa 20 mg QW, Efsubaglutide Alfa 40 mg QW, Efsubaglutide Alfa 40 mg Q2W - Obesity and Overweight | Phase 2 | Recruiting | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | 200 | 2025-08-25 | 2025-12-02 |
| Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients Efsubaglutide Alfa 3mg Q2W and 1mg QW, Efsubaglutide Alfa 1mg QW and 3mg Q2W - Type 2 Diabetes | Phase 3 | Not yet recruiting | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | 88 | 2025-07-30 | 2025-03-28 |
| The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT) Phase IIb：Efsubaglutide Alfa 5 mg QW, Phase IIb：Efsubaglutide Alfa 10 mg QW, Phase IIb：Efsubaglutide Alfa 20 mg QW - Obesity and Overweight | Phase 2 / Phase 3 | Active not recruiting | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | 1003 | 2025-03-31 | 2026-01-30 |
| A Study of 3mg Once Every Two Weeks Administration of Efsubaglutide Alfa Injection in Type 2 Diabetes Patients. Efsubaglutide Alfa Injection - Type2 Diabetes | Phase 2 | Completed | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | 59 | 2024-12-18 | 2025-09-12 |
| A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity Patients Efsubaglutide Alfa, Placebo - Overweight or Obesity | Phase 2 | Completed | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | 50 | 2024-04-21 | 2025-04-02 |
| Drug Drug Interaction (DDI) Between Supaglutide and Digoxin or Metformin Supaglutide injection, Digoxin, Metformin - Healthy Volunteers | Phase 1 | Completed | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | 34 | 2023-03-20 | 2024-08-05 |
| A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients On Metformin Treatment(SUPER-2) supaglutide injection+metformin, placebo+metformin - Type2 Diabetes | Phase 2 / Phase 3 | Completed | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | 620 | 2021-10-12 | 2024-12-06 |
| A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients(SUPER-1) Supaglutide injection, placebo injection - Type2 Diabetes | Phase 2 / Phase 3 | Completed | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | 547 | 2021-08-03 | 2024-08-07 |
| A Study of Supaglutide in Chinese Type 2 Diabetes Patients Supaglutide, Placebo - Diabetes Mellitus, Type 2 | Phase 2 | Completed | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | 40 | 2020-04-14 | 2021-09-17 |
| A Study of the Efficacy and Safety of Supaglutide in Healthy Participants Supaglutide injection, Placebo - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | 48 | 2018-12-04 | 2021-09-17 |
Diabetes Mellitus, Type 2 (4) · Obesity (3) · Overweight (3) · Pediatric Obesity (1) · Weight Loss (1)
China (9) · Australia (1) · Brazil (1)
Weiping Jia, M.D,Ph. D (2) · Dalong Zhu, M.D,Ph.D (1) · Jing Zhang (1) · Karen Kaluhin (1) · Weiping Jia, Doctor (1) · Weiping Jia, M.D,Ph.D (1) · Yuqian Bao, Doctor (1)
PMID 39961992, PMID 40587051, PMID 40991141, PMID 41107649, PMID 41272211, PMID 42103705